Lumexa Imaging Holdings (LMRI) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

$0.20

Estimate

$0.14

Surprise

+38.9%

Revenue (period 2026-06-30)

$264.2M

Score today

4.9/10

Revenue source: xbrl.

Lumexa Imaging Holdings (LMRI) beat the $0.14 estimate with diluted EPS of $0.20 — a large 38.9% upside surprise.

• Lumexa Imaging Holdings Affirms FY2026 Adj EPS Guidance of $0.71-$0.77 vs $0.62 Est; Raises FY2026 Sales Guidance from $ — benzinga, 2026-08-12
• Lumexa Imaging Holdings Q2 Adj. EPS $0.20 Beats $0.16 Estimate, Sales $264.200M Beat $263.113M Estimate — benzinga, 2026-08-12

TrendMatrix currently rates LMRI Sell at 4.9/10; no pre/post engine snapshot brackets this report.

1 of the last 2 quarters beat the estimate; this quarter's +38.9% surprise compares with a -19.5% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$12.27

Price target

$15.29

Stop

$11.45

Upside to target

+24.6%

Reward-to-risk

2.6:1

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Devices

Market cap

$1.14B

P/E (fwd)

13.1

52-week range

$6.45–$19.45

Off 52-week high

36.9%

RSI (14)

57

Volume vs avg

0.28×

Score today

4.9/10